Engineering monoclonal antibodies for COVID-19 prophylaxis.

Izadpanah, Amin; Rappaport, Jay

Izadpanah, Amin; Rappaport, Jay.

Izadpanah A; Tulane National Primate Research Center, Department of Microbiology and Immunology, Tulane University School of Medicine, 18703 Three Rivers Road, Covington LA 70411, USA.
Rappaport J; Tulane National Primate Research Center, Department of Microbiology and Immunology, Tulane University School of Medicine, 18703 Three Rivers Road, Covington LA 70411, USA.

Med (N Y) ; 3(3): 157-158, 2022 03 11.

Article in English | MEDLINE | ID: covidwho-1734815

ABSTRACT

ABSTRACT

The therapeutic and prophylactic uses of monoclonal antibodies (mABs) against SARS-CoV-2 are limited by their short half-life and need for intravenous delivery. In this issue, Cobb et al.1 engineer a neutralizing mAB cocktail with extended half-life that can be delivered intramuscularly to provide prophylactic protection against infection in rhesus macaques.

Subject(s)

Antineoplastic Agents, Immunological; COVID-19; Animals; Antibodies, Monoclonal/therapeutic use; Antibodies, Neutralizing/therapeutic use; COVID-19/prevention & control; Humans; Macaca fascicularis/immunology; Macaca mulatta/immunology; SARS-CoV-2; Spike Glycoprotein, Coronavirus/immunology

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antineoplastic Agents, Immunological / COVID-19 Limits: Animals / Humans Language: English Journal: Med (N Y) Year: 2022 Document Type: Article Affiliation country: J.medj.2022.02.004

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google